News

News

Press Releases

Aug 08, 2019
Tricida Announces Second Quarter 2019 Financial Results
Narrows Timing of Planned NDA Submission to the Third Quarter of 2019 Back-to-Back Publications in ‘The Lancet’ Highlight Positive Clinical Trial Results of Veverimer Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 8, 2019-- Tricida, Inc.
May 08, 2019
Tricida Announces First Quarter 2019 Financial Results
Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 8, 2019-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed
Apr 03, 2019
Tricida Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 3, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced the pricing of its public offering of 5,600,000 shares of its common stock at a public offering price of $36.00 per share for total gross proceeds of $201.6 million , before deducting
Apr 01, 2019
Tricida Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 1, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares in the offering will be sold by Tricida .